6-Gingerol Protects Heart by Suppressing Myocardial Ischemia/Reperfusion Induced Inflammation via the PI3K/Akt-Dependent Mechanism in Rats.
Tongtong XuGuowei QinWei JiangYing ZhaoYongnan XuXiang-Wei LvPublished in: Evidence-based complementary and alternative medicine : eCAM (2018)
Our previous study has demonstrated that 6-Gingerol (6-G) could alleviate myocardial ischemia/reperfusion injury (MIRI). However, the molecular mechanism underlying the process of myocardial ischemia/reperfusion (I/R) injury alleviation by 6-G remains unelucidated. The objective of the present study is to further investigate the potential mechanism for 6-G to alleviate MIRI in rats. Thirty-two Sprague-Dawley rats were randomly divided into four groups: the Sham group, the I/R group, the 6-G + I/R group, and the LY294002 (LY) + 6-G + I/R group. For the rats in each of the groups, data were collected for cardiogram, cardiac function, area of myocardial infarction, myocardial pathology, myocardial enzyme, marker of inflammatory response, and PI3K/Akt signaling pathway. We found that the pretreatment of 6-G with 6 mg/kg could shrink the ST section of cardiogram, improve the cardiac function, reduce the area of myocardial infarction and the degree of cardiac pathological injury, lower the level of myocardial enzyme, and inhibit the inflammatory response. In addition, our results also indicated that 6-G could upregulate the expression of PI3K and p-Akt and that LY294002, a blocking agent of PI3K/Akt signaling pathway, could nullify the protecting role of 6-G. Our experimental results showed that 6-G could inhibit I/R-induced inflammatory response through the activation of the PI3K/Akt signaling pathway.
Keyphrases
- pi k akt
- signaling pathway
- left ventricular
- inflammatory response
- cell proliferation
- cell cycle arrest
- induced apoptosis
- heart failure
- epithelial mesenchymal transition
- oxidative stress
- lipopolysaccharide induced
- ischemia reperfusion injury
- toll like receptor
- diabetic rats
- lps induced
- high glucose
- poor prognosis
- immune response
- clinical trial
- machine learning
- risk assessment
- deep learning
- climate change
- double blind